Alkermes plc.
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
ALKS | NDAQ
Overview
Corporate Details
- ISIN(s):
- IE00B56GVS15 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- CONNAUGHT HOUSE, 0 DUBLIN 4
- Website:
- https://www.alkermes.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Alkermes plc is a global biopharmaceutical company that develops innovative medicines for central nervous system (CNS) disorders. The company focuses on psychiatric and neurological conditions, with a portfolio of commercial products and a pipeline of investigational therapies. Its approved treatments include an oral atypical antipsychotic drug, a combination of olanzapine and samidorphan, for adults with schizophrenia and bipolar I disorder. Alkermes' research and development pipeline is centered on neuroscience and includes several orexin 2 receptor agonist candidates in clinical development for sleep disorders such as narcolepsy and idiopathic hypersomnia, as well as other CNS indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Alkermes plc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alkermes plc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alkermes plc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
